|Dr. Ying Du Ph.D.||Founder, Chairperson & CEO||1.64M||103.18M||1966|
|Mr. Ki Chul Cho||Chief Financial Officer||720.97k||N/A||1978|
|Mr. Frazor Titus Edmondson III||Chief Legal Officer & Corp. Sec.||829k||N/A||1966|
|Dr. Harald Reinhart M.D.||Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases||845.94k||13.92M||1952|
|Dr. Alan Bart Sandler M.D.||Pres & Head of Global Devel. in Oncology||1.19M||N/A||1957|
|Ms. Ann Beasley||Chief Compliance Officer||N/A||N/A||N/A|
|Dr. Ning Xu M.D.||Exec. VP & Head of Clinical Operations||N/A||N/A||1965|
|Dr. Jonathan J. Wang M.B.A., MBA, Ph.D.||Exec. VP & Head of Bus. Devel.||N/A||N/A||1982|
|Dr. James Yan DABT, M.D., Ph.D.||Chief Operating Officer of R&D||N/A||N/A||1964|
|Mr. Yi Liang M.B.A., M.D.||Chief Commercial Officer & Pres of Greater China||N/A||N/A||1971|
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Zai Lab Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.